Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 771 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease Sickle Cell Anemia Clear all
Terminated Phase 3 Interventional Results available

Voxelotor Neurocognitive Function Study

NCT05228834
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor Only Product in Oral Dose Form, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 29, 2026, 11:48 AM EDT
Completed No phase listed Observational

Developing the Family Map: Looking at Communal Coping

NCT01633021
View directory record Official record
Conditions
Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Active, not recruiting Phase 1 Interventional

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

NCT03664830
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional Results available

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 29, 2026, 11:48 AM EDT
Active, not recruiting Phase 1 Interventional

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT03249831
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions
Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Terminated Phase 4 Interventional Results available

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

NCT00115336
View directory record Official record
Conditions
Hematologic Diseases, Anemia, Sickle Cell
Interventions
Intravenous Ketorolac, Ibuprofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 29, 2026, 11:48 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704
View directory record Official record
Conditions
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional

A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease

NCT01800526
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 29, 2026, 11:48 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 29, 2026, 11:48 AM EDT
Not listed No phase listed Observational

STRIDE Biorepository

NCT02843347
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Blood draw
Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

NCT00270478
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
Interventions
Erythropoietin and Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Not applicable Interventional Results available

PATient Navigator to rEduce Readmissions

NCT02114515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction, Pneumonia
Interventions
Hospital usual care, Navigator intervention, Peer-led telephone support line
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Exercise on Biomarkers in SCT

NCT04273022
View directory record Official record
Conditions
Sickle Cell Trait
Interventions
Exercise
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 29, 2026, 11:48 AM EDT
Recruiting No phase listed Observational

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

NCT04093986
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Chart Review, Survey
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

NCT03285178
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
IW-1701, Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Orange, California • Washington D.C., District of Columbia • Aventura, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Program to Increase Sickle Cell Trait Knowledge Among Parent of Young Children Identified in Newborn Screening

NCT03984500
View directory record Official record
Conditions
Sickle Cell Trait
Interventions
Education
Other
Lead sponsor
Susan Creary
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 29, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

School Readiness Intervention for Preschool Children With Sickle Cell Disease

NCT06367192
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
The adapted Kids in Transition to School Intervention, Standard school resources
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
42 Months to 78 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Health Workers and mHealth for Sickle Cell Disease Care

NCT03648710
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Peer Community Health Worker, Mobile Health
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
17 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
5
States / cities
Hartford, Connecticut • New Hyde Park, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Not applicable Interventional

MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)

NCT03556657
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Music Therapy
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 29, 2026, 11:48 AM EDT
Recruiting Phase 2 Interventional

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

NCT07023666
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
Drug · Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Recruiting Phase 1 Interventional

Gene Editing For Sickle Cell Disease

NCT06506461
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor, Busulfan, Gene-modified CD34+ cells, Motixafortide
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
alpha-lipoic acid and acetyl-L-carnitine, Control
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 29, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

NCT01136941
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Zileuton
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 29, 2026, 11:48 AM EDT